Araştırma Makalesi
BibTex RIS Kaynak Göster

No Association between Foxp3 Promoter Region Polymorphisms (rs3761548 and rs2232365) and Crimean Congo Hemorrhagic Fever Disease

Yıl 2018, Cilt: 12 Sayı: 2, 25 - 27, 25.09.2018

Ergun Pinarbasi Nilgun Cekin Aslihan Esra Bildirici Mehmet Bakir Serdal Arslan

Öz

Crimean-Congo hemorrhagic fever (CCHF) is a tick-borne, viral disease that causes severe outbreaks in people throughout large geographical areas. The common feature of viral hemorrhagic fever (VHF) cases is the attack on the cells that initiate the antiviral response and the impaired immune response of the host. There is no study of the variation of the promoter region of Foxp3 gene, which has been shown to be involved in inflammation in studies of autoimmune diseases, in relation to the risk or susceptibility of disease in CCHF patients. Therefore, the aim of our study was to investigate Foxp3 rs3761548 and rs2232365 gene polymorphisms in patients with CCHF. Blood samples taken from 80 CCHF patients and 80 healthy subjects were used in the study. Genotyping was performed by PCR-RFLP followed by total DNA isolation. No statistically significant relationship between Foxp3 gene polymorphisms rs2232365 and rs3761548 and CCHF was found.Although the pathophysiology of CCHF is still not fully understood, there are some mechanisms shown to be related to the immune system. Studies examining other variants in the Foxp3 gene promoter region and of exon and intron mutations may yield beneficial results in terms of the association between gene and disease progression.

Anahtar Kelimeler

Crimean-Congo hemorrhagic fever Foxp3 polymorphism

Kaynakça

  • Elaldı N. 2004. Kırım-Kongo hemorajik ateş epidemiyolojisi. C.Ü. Tıp Fakültesi Dergisi, 26(4):185-190.
  • Ergonul O. 2006. Crimean-Congohaemorrhagicfever. LancetInfect. Dis.,6:203-214.
  • Buttigieg KR, Dowall SD, Findlay-Wilson S, Miloszewska A, Rayner E, Hewson R, Carroll MW. 2014. A novelvaccineagainstCrimean-Congohaemorrhagicfeverprotects 100% of animalsagainstlethalchallenge in a Mouse model. PlosOne, 9(3):e91516.
  • Leblebicioglu H, Ozaras R, Irmak H, Sencan I. 2016. Crimean-Congohaemorrhagicfever in Turkey: Currentstatus and futurechallenges. Antiviral Research, 126:21-34.
  • Ministry of Health, Turkey. Reports of thecommunicablediseasesdepartment (2008) Ankara (Turkey) (in Turkish). Available at: http://www.saglik.gov.tr
  • Ozkurt Z. 2007. Kırım-Kongo kanamalı ateşi. Yoğun Bakım Dergisi, 7(1):85-90.
  • Elaldi N, Kaya S. 2014. Crimean-Congohaemorrhagicfever. JMID, 1:1-9.
  • Esen F. 2008. CD4+T hücrelerinde güncel gelişmeler: Th17 hücreleri. Cerrahpaşa Öğrenci Bilimsel Dergisi, 1(1).
  • Weaver CT, Harrington LE, Mangan PR, Gavrielli M, Murphy KM. 2006. Th17: An effector CD4 T celllineagewithregulatory T cellties. Immunity, 24:677-688.
  • Oda JMM, Hirata BKB, Guembarovski RL, Watanabe MAE. 2013. Geneticpolymorphism in Foxp3 gene: imbalance in regulatory T cell role and development of humandiseases. J Genet.,92:163-171.
  • Wildin RS, Smyk-Pearson S, Filipovich AH. 2002. Clinical and molecularfeatures of theimmunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J MedGenet, 39:537-545.
  • Engin A, Arslan S, Kizildag S, Ozturk H, Elaldi N, Dokmetas I, Bakir M. 2010. Tool-likereceptor 8 and 9 polymorphisms in Crimean-Congohemorrhagicfever. Microbes and Infection, 12:1071-1078.
  • Hanel SA, Velavan TP, Kremsner PG, Kun JF. 2011. Novel and functionalregulatorySNPs in thepromoterregion of Foxp3 gene in a Gabonesepopulation. Immunogenetics, 63:409-415.
  • Bassuny WM, Ihara K, Sasaki Y, Kuromaru R, Kohno H, Matsuura N, Hata T. 2003. A functionalpolymorphism in thepromoter/enhancerregion of theFoxp3/Scurfin gene associatedwithtype 1 diabetes. Immunogenetics, 55:149-156.
  • Ullrich A, Shine J, Chirgwin J, et al. 1997. Rat insülin genes: construction of plasmidscontainingthecodingsequences. Science, 196(4296):1313-1319.
  • Geisbert TW, Jahrling PB. 2004. Exoticemerging viral diseases: progress and challenges. NatMed, 10:110-121.
  • Singer BD, King LS, D’Alessio FR. 2014. Regulatory T cells as immunotherapy. Front Immunol, 5:46.
  • Lund JM, Hsing L, Pham TT, Rudensky AY. 2008. Coordination of earlyprotectiveimmunityto viral infectionbyregulatory T cells. Science, 320(5880):1220-1224.
  • Swanepoel R, Gill DE, ShepherdAj, Leman PA, Mynhardt JH, Harvey S. 1989. Theclinicalpathology of Crimean-Congohaemorrahagicfever. RevInfectDis, 4:794-800.
  • Sun L, Wu J and Yi S. 2012. Foxp3 is criticalforhumannatural CD4+CD25+ regulatory T cellstosuppressalloimmuneresponse. TransplImmunol, 26:71-80.
  • Kaya S, Elaldi N, Kubar A, Gursoy N, Yilmaz M, Karakus G, Gunes T, Polat Z, Gozel MG, Engin A, Dokmetas I, Bakir M, Yilmaz N, Sencan M. 2014. Sequentialdetermination of serum viral titers, virüs-specificIgGantibodies, and TNF-α, IL-6, IL-10, and IFN-γ levels in patientswithCrimean-Congohemorrhagicfever. BMC InfectDis, 14:416.
  • Yilmaz M, Elaldi N, Bagci B, Sari I, Gumus E, Yelkovan I. 2015. Effect of tumournecrosisfactor-alpha and interleukin-6 promoterpolymorphisms on course of Crimean-Congohemorrhagicfever in Turkishpatients. J VectorBorneDis, 52:30-35.
  • Akinci E, Bodur H, Leblebicioglu H. 2013. Pathogenesis of Crimean-Congohemorrhagicfever. VectorBorneZoonoticDis, 13:429-437.

Yıl 2018, Cilt: 12 Sayı: 2, 25 - 27, 25.09.2018

Ergun Pinarbasi Nilgun Cekin Aslihan Esra Bildirici Mehmet Bakir Serdal Arslan

Öz

Kaynakça

  • Elaldı N. 2004. Kırım-Kongo hemorajik ateş epidemiyolojisi. C.Ü. Tıp Fakültesi Dergisi, 26(4):185-190.
  • Ergonul O. 2006. Crimean-Congohaemorrhagicfever. LancetInfect. Dis.,6:203-214.
  • Buttigieg KR, Dowall SD, Findlay-Wilson S, Miloszewska A, Rayner E, Hewson R, Carroll MW. 2014. A novelvaccineagainstCrimean-Congohaemorrhagicfeverprotects 100% of animalsagainstlethalchallenge in a Mouse model. PlosOne, 9(3):e91516.
  • Leblebicioglu H, Ozaras R, Irmak H, Sencan I. 2016. Crimean-Congohaemorrhagicfever in Turkey: Currentstatus and futurechallenges. Antiviral Research, 126:21-34.
  • Ministry of Health, Turkey. Reports of thecommunicablediseasesdepartment (2008) Ankara (Turkey) (in Turkish). Available at: http://www.saglik.gov.tr
  • Ozkurt Z. 2007. Kırım-Kongo kanamalı ateşi. Yoğun Bakım Dergisi, 7(1):85-90.
  • Elaldi N, Kaya S. 2014. Crimean-Congohaemorrhagicfever. JMID, 1:1-9.
  • Esen F. 2008. CD4+T hücrelerinde güncel gelişmeler: Th17 hücreleri. Cerrahpaşa Öğrenci Bilimsel Dergisi, 1(1).
  • Weaver CT, Harrington LE, Mangan PR, Gavrielli M, Murphy KM. 2006. Th17: An effector CD4 T celllineagewithregulatory T cellties. Immunity, 24:677-688.
  • Oda JMM, Hirata BKB, Guembarovski RL, Watanabe MAE. 2013. Geneticpolymorphism in Foxp3 gene: imbalance in regulatory T cell role and development of humandiseases. J Genet.,92:163-171.
  • Wildin RS, Smyk-Pearson S, Filipovich AH. 2002. Clinical and molecularfeatures of theimmunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J MedGenet, 39:537-545.
  • Engin A, Arslan S, Kizildag S, Ozturk H, Elaldi N, Dokmetas I, Bakir M. 2010. Tool-likereceptor 8 and 9 polymorphisms in Crimean-Congohemorrhagicfever. Microbes and Infection, 12:1071-1078.
  • Hanel SA, Velavan TP, Kremsner PG, Kun JF. 2011. Novel and functionalregulatorySNPs in thepromoterregion of Foxp3 gene in a Gabonesepopulation. Immunogenetics, 63:409-415.
  • Bassuny WM, Ihara K, Sasaki Y, Kuromaru R, Kohno H, Matsuura N, Hata T. 2003. A functionalpolymorphism in thepromoter/enhancerregion of theFoxp3/Scurfin gene associatedwithtype 1 diabetes. Immunogenetics, 55:149-156.
  • Ullrich A, Shine J, Chirgwin J, et al. 1997. Rat insülin genes: construction of plasmidscontainingthecodingsequences. Science, 196(4296):1313-1319.
  • Geisbert TW, Jahrling PB. 2004. Exoticemerging viral diseases: progress and challenges. NatMed, 10:110-121.
  • Singer BD, King LS, D’Alessio FR. 2014. Regulatory T cells as immunotherapy. Front Immunol, 5:46.
  • Lund JM, Hsing L, Pham TT, Rudensky AY. 2008. Coordination of earlyprotectiveimmunityto viral infectionbyregulatory T cells. Science, 320(5880):1220-1224.
  • Swanepoel R, Gill DE, ShepherdAj, Leman PA, Mynhardt JH, Harvey S. 1989. Theclinicalpathology of Crimean-Congohaemorrahagicfever. RevInfectDis, 4:794-800.
  • Sun L, Wu J and Yi S. 2012. Foxp3 is criticalforhumannatural CD4+CD25+ regulatory T cellstosuppressalloimmuneresponse. TransplImmunol, 26:71-80.
  • Kaya S, Elaldi N, Kubar A, Gursoy N, Yilmaz M, Karakus G, Gunes T, Polat Z, Gozel MG, Engin A, Dokmetas I, Bakir M, Yilmaz N, Sencan M. 2014. Sequentialdetermination of serum viral titers, virüs-specificIgGantibodies, and TNF-α, IL-6, IL-10, and IFN-γ levels in patientswithCrimean-Congohemorrhagicfever. BMC InfectDis, 14:416.
  • Yilmaz M, Elaldi N, Bagci B, Sari I, Gumus E, Yelkovan I. 2015. Effect of tumournecrosisfactor-alpha and interleukin-6 promoterpolymorphisms on course of Crimean-Congohemorrhagicfever in Turkishpatients. J VectorBorneDis, 52:30-35.
  • Akinci E, Bodur H, Leblebicioglu H. 2013. Pathogenesis of Crimean-Congohemorrhagicfever. VectorBorneZoonoticDis, 13:429-437.
Toplam 23 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Bölüm Araştırma Makalesi
Yazarlar

Ergun Pinarbasi

Nilgun Cekin Bu kişi benim

Aslihan Esra Bildirici Bu kişi benim

Mehmet Bakir Bu kişi benim

Serdal Arslan Bu kişi benim

Yayımlanma Tarihi 25 Eylül 2018
Yayımlandığı Sayı Yıl 2018 Cilt: 12 Sayı: 2

Kaynak Göster

APA Pinarbasi, E., Cekin, N., Bildirici, A. E., Bakir, M., vd. (2018). No Association between Foxp3 Promoter Region Polymorphisms (rs3761548 and rs2232365) and Crimean Congo Hemorrhagic Fever Disease. Journal of Applied Biological Sciences, 12(2), 25-27.
AMA Pinarbasi E, Cekin N, Bildirici AE, Bakir M, Arslan S. No Association between Foxp3 Promoter Region Polymorphisms (rs3761548 and rs2232365) and Crimean Congo Hemorrhagic Fever Disease. J.appl.biol.sci. Eylül 2018;12(2):25-27.
Chicago Pinarbasi, Ergun, Nilgun Cekin, Aslihan Esra Bildirici, Mehmet Bakir, ve Serdal Arslan. “No Association Between Foxp3 Promoter Region Polymorphisms (rs3761548 and rs2232365) and Crimean Congo Hemorrhagic Fever Disease”. Journal of Applied Biological Sciences 12, sy. 2 (Eylül 2018): 25-27.
EndNote Pinarbasi E, Cekin N, Bildirici AE, Bakir M, Arslan S (01 Eylül 2018) No Association between Foxp3 Promoter Region Polymorphisms (rs3761548 and rs2232365) and Crimean Congo Hemorrhagic Fever Disease. Journal of Applied Biological Sciences 12 2 25–27.
IEEE E. Pinarbasi, N. Cekin, A. E. Bildirici, M. Bakir, ve S. Arslan, “No Association between Foxp3 Promoter Region Polymorphisms (rs3761548 and rs2232365) and Crimean Congo Hemorrhagic Fever Disease”, J.appl.biol.sci., c. 12, sy. 2, ss. 25–27, 2018.
ISNAD Pinarbasi, Ergun vd. “No Association Between Foxp3 Promoter Region Polymorphisms (rs3761548 and rs2232365) and Crimean Congo Hemorrhagic Fever Disease”. Journal of Applied Biological Sciences 12/2 (Eylül 2018), 25-27.
JAMA Pinarbasi E, Cekin N, Bildirici AE, Bakir M, Arslan S. No Association between Foxp3 Promoter Region Polymorphisms (rs3761548 and rs2232365) and Crimean Congo Hemorrhagic Fever Disease. J.appl.biol.sci. 2018;12:25–27.
MLA Pinarbasi, Ergun vd. “No Association Between Foxp3 Promoter Region Polymorphisms (rs3761548 and rs2232365) and Crimean Congo Hemorrhagic Fever Disease”. Journal of Applied Biological Sciences, c. 12, sy. 2, 2018, ss. 25-27.
Vancouver Pinarbasi E, Cekin N, Bildirici AE, Bakir M, Arslan S. No Association between Foxp3 Promoter Region Polymorphisms (rs3761548 and rs2232365) and Crimean Congo Hemorrhagic Fever Disease. J.appl.biol.sci. 2018;12(2):25-7.